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Background: Exosomes are nanovesicles secreted by tumour cells which have roles in paracrine signalling during
tumour progression, including tumour-stromal interactions, activation of proliferative pathways and bestowing
immunosuppression. Hypoxia is an important feature of solid tumours which promotes tumour progression,
angiogenesis and metastasis, potentially through exosome-mediated signalling.
Methods: Breast cancer cell lines were cultured under either moderate (1% O2) or severe (0.1% O2) hypoxia.
Exosomes were isolated from conditioned media and quantitated by nanoparticle tracking analysis (NTA) and
immunoblotting for the exosomal protein CD63 in order to assess the impact of hypoxia on exosome release.
Hypoxic exosome fractions were assayed for miR-210 by real-time reverse transcription polymerase chain reaction
and normalised to exogenous and endogenous control genes. Statistical significance was determined using the
Student T test with a P value of < 0.05 considered significant.
Results: Exposure of three different breast cancer cell lines to moderate (1% O2) and severe (0.1% O2) hypoxia
resulted in significant increases in the number of exosomes present in the conditioned media as determined by
NTA and CD63 immunoblotting. Activation of hypoxic signalling by dimethyloxalylglycine, a hypoxia-inducible
factor (HIF) hydroxylase inhibitor, resulted in significant increase in exosome release. Transfection of cells with
HIF-1α siRNA prior to hypoxic exposure prevented the enhancement of exosome release by hypoxia. The
hypoxically regulated miR-210 was identified to be present at elevated levels in hypoxic exosome fractions.
Conclusions: These data provide evidence that hypoxia promotes the release of exosomes by breast cancer cells,
and that this hypoxic response may be mediated by HIF-1α. Given an emerging role for tumour cell-derived
exosomes in tumour progression, this has significant implications for understanding the hypoxic tumour
phenotype, whereby hypoxic cancer cells may release more exosomes into their microenvironment to promote
their own survival and invasion.
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Exosomes are biological nanovesicles (30 – 100 nm in
diameter) constitutively released by cells through the fu-
sion of multivesicular endosomes with the plasma mem-
brane and subsequent release of intraluminal vesicles
into the extracellular environment [1,2]. Exosomes con-
tain a wide range of functional proteins, mRNAs and
microRNAs (miRNAs) [3-5], providing a novel paracrine* Correspondence: Jonathan.Gleadle@health.sa.gov.au
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reproduction in any medium, provided the orsignalling mechanism during important physiological pro-
cesses, including tumour progression. Exosome-mediated
signalling promotes tumour progression through com-
munication between the tumour and surrounding stro-
mal tissue [6], activation of proliferative and angiogenic
pathways [5,7], by bestowing immune suppression [8,9],
and initiation of pre-metastatic sites [10]. The factors
and stimuli that regulate exosome release are not fully
understood, although roles have been reported for p53
[11,12], ceramide synthesis [13], calcium signalling [14],
and acidosis [15].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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environment that arises due to an imbalance in the sup-
ply and consumption of oxygen by tumour cells [16].
Hypoxic tumours exhibit more aggressive phenotypes
and are associated with poor patient outcome in a wide
variety of cancers [17]. The cellular response to hypoxia
is largely mediated by the hypoxia-inducible factor (HIF)
family of transcription factors, and results in global tran-
scriptional changes in gene expression, including genes
with roles in promoting tumour progression, angiogen-
esis and metastasis [16,18]. The HIF family isoforms
(HIF-1α, -2α and -3α) are targeted for degradation under
normal oxygen conditions (normoxia; 21% O2) by the
action of specific O2-, iron- and 2-oxoglutarate depen-
dent prolyl hydroxylases [16]. Inhibition of these prolyl
hydroxylases under normoxic conditions therefore pre-
vents degradation of the HIF family, allowing them to
bind and regulate their transcriptional target genes [19].
Recent evidence has highlighted a role for hypoxic tu-
mour cell-derived exosomes in promoting angiogenic
signalling [20,21], and there is evidence in several sys-
tems for enhanced microvesicle or microparticle release
under hypoxia [22,23] and anoxia [24]. Given the ob-
servations which independently link both hypoxia and
exosome-mediated signalling to invasive tumour pheno-
types, it is of interest to investigate if hypoxia might pro-
mote tumour progression through altered exosome
release. Here we present data which demonstrate that
breast cancer cells exposed to hypoxia release higher
numbers of exosomes than cells under normoxia, and
that this may be mediated by the HIF oxygen sensing
system.
Methods
Cell culture
The breast cancer cell lines MCF7, SKBR3, and MDA-
MB 231 were cultured at 37°C in a 5% CO2 humidified
environment as adherent monolayers in RPMI 1640
media (Sigma-Aldrich) supplemented with 5% fetal calf
serum (FCS) (Sigma-Aldrich), RPMI 1640 with 10% FCS,
or DMEM media (Sigma-Aldrich) with 10% FCS re-
spectively. For exosome isolation, cells were cultured in
media supplemented with exosome-depleted FCS. FCS
was depleted of bovine exosomes by ultracentrifugation
at 100,000 × g for 16 hours at 4°C. Cell counts were per-
formed using a haemocytometer and viability was de-
termined by 0.1% (w/v) Trypan blue (Sigma-Aldrich)
exclusion. Transfections were performed using Lipofec-
tamine 2000 (Invitrogen) as described by the manufac-
turer. HIF-1α siRNA (sense 50-CUGAUGACCAGCAAC
UUGAdTdT-30 and antisense 50-UCAAGUUGCUGGU
CAUCAGdTdT-30) and negative control siRNA (sense
50-UUCUCCGAACGUGUCACGUTT-30 and antisense
50-ACGUGACACGUUCGGAGAATT-30) were purchasedfrom Shanghai GenePharma and used at a final con-
centration of 20 nM as previously described [25].
Hypoxic exposure
Hypoxic experiments were performed within a Hypoxic
Glove Box (Coy Laboratory Products) at either 1% or
0.1% O2 at 37°C in a 5% CO2 humidified environment
with the balance provided by nitrogen. Alternatively,
cells were treated with the HIF hydroxylase inhibitor
dimethyloxalylglycine (DMOG) (Enzo Life Sciences) at a
final concentration of 1 mM.
Exosome isolation
To assess exosome release, cells were seeded at least
24 hours prior to hypoxia or other treatments to allow
cells to attach and achieve a growth phase. After culture
in the presence or absence of hypoxia, conditioned me-
dia was harvested for exosome isolation. Exosomes are
traditionally isolated from conditioned media by serial
centrifugation at low speed, followed by ultracentrifuga-
tion at 100,000 × g to pellet the exosomes [26,27]. Re-
cently a proprietary method of exosome isolation called
ExoquickTM has been made commercially available, which
is reported to provide a rapid and efficient method for
exosome isolation [28]. Conditioned media underwent
serial centrifugation (300 × g; 10 min, 2000 × g; 10 min,
10,000 × g; 30 min) prior to exosome isolation by ultra-
centrifugation (100,000 × g; 70 min) or ExoquickTM pre-
cipitation. Exosome precipitation with the ExoquickTM
reagent (System Biosciences) was performed according
to the manufacturer’s instructions. Pelleted exosomes
were resuspended in phosphate buffered saline and
stored at −20°C. Cell counts and viability were also
determined at the time of harvest in order to account
for differences in cell growth (Additional File 1).
Electron microscopy
Exosome fractions were fixed with paraformaldehyde to
copper mesh formvar grids (ProSciTech) and immu-
nolabelled with mouse monoclonal anti-human CD63
(BD PharminigenTM) and a gold-labelled (10 nm) goat anti-
mouse IgG secondary antibody (Sigma-Aldrich). Grids were
further fixed with 1% glutaraldehyde and negatively stained
by 0.5% uranyl acetate. Samples were observed using the
JEOL 1200EX Transmission Electron Microscope housed
at Flinders Medical Centre, Bedford Park.
Nanosight nanoparticle tracking analysis
Isolated exosomes were analysed using the Nanosight
LM10 system (Nanosight Ltd) [29,30] equipped with a
blue laser (405 nm). Nanoparticles were illuminated by
the laser and their movement under Brownian motion
was captured for 60 seconds. For example of video cap-
tures, see Additional File 2. Videos were then subjected
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sight particle tracking software to provide nanoparticle
concentrations and size distribution profiles. At least
three videos were captured for each individual sample
to provide a representative concentration measurement,
and all analysis settings were kept constant within each
experiment. Size distribution profiles obtained from
NTA were averaged within each sample across the video
replicates, and then averaged across samples to provide
representative size distribution profiles. These distribu-
tion profiles were then normalised to total nanoparticle
concentrations or final cell counts.
SDS-PAGE and immunoblotting
Exosomal fractions were resolved by polyacrylamide
gel electrophoresis and electroblotted onto polyvinyli-
dene difluoride membrane (Millipore). Non-reducing
conditions were used for CD63 immunoblots due to
the sensitivity of the antibody epitope to reducing
conditions, as described previously [26]. Primary anti-
bodies used were mouse monoclonal anti-human CD63
(BD PharminigenTM), mouse monoclonal anti-human CD9
(Santa Cruz Biotechnology), rabbit polyclonal anti-human
Tsg101 (Tumour susceptibility gene 101) (Abcam),
mouse monoclonal anti-mouse flotillin-1 (BD TransductionFigure 1 Exosome isolation by ultracentrifugation and ExoquickTM pr
electron microscopy and CD63 immunolabelling of MCF7 exosomes isolate
(C) Nanoparticle tracking analysis (NTA) of MCF7 exosomes isolated by ultra
average size distribution profile of n = 4 for each purification method norm
sample derive from four different videos and analyses. (D) Immunoblotting
cofilin and flotillin-1.LaboratoriesTM), and rabbit polyclonal anti-human cofilin-1
(Cell Signaling Technology). The horseradish peroxidase-
conjugated secondary antibodies donkey anti-mouse IgG
and goat anti-rabbit IgG (Immunopure) were used with
enhanced chemiluminescence detection SuperSignal West
Pico (Thermo Scientific). Membranes were visualised with
the ImageQuant LAS 4000 system (GE Healthcare
Life Sciences) or the BioRad ChemiDocTM MP Imaging
System (Bio-Rad Laboratories). Band intensity quan-
titation was performed using MultiGauge software
(FujiFilm).
RNA extraction and real-time RT-PCR
Cells and isolated exosomes had RNA extracted using
the TRIzolW reagent (Invitrogen). Exosome preparations
were spiked with synthetic Caenorhabditis elegans miR-
54 (cel miR-54) prior to homogenisation by TRIzol as
previously described [31]. TaqMan miRNA-specific pri-
mers and reverse transcription kits (Applied Biosystems)
were used to synthesize cDNA. miRNA-specific cDNA
was then used for relative quantitation by real-time re-
verse transcription polymerase chain reaction (real-time
RT-PCR) with TaqMan Universal PCR Master Mix and
the appropriate TaqMan miRNA assay (Assay IDs: miR-
210: 000512, miR-21: 000397, miR-16: 000391, let7a:ecipitation from MCF7 conditioned media. (A, B) Transmission
d by ultracentrifugation (A) and ExoquickTM precipitation (B).
centrifugation and ExoquickTM precipitation. Data represent the
alised to the total nanoparticle concentrations. Data for each individual
of ultracentrifugation pellet for exosomal proteins CD63, TSG101,
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Figure 2 Comparison of exosome isolation efficiency by
ultracentrifugation and ExoquickTM precipitation. (A) Exosome
fractions from ultracentrifugation or ExoquickTM precipitation were
analysed by NTA. Nanoparticle concentrations per mL of original
volume of media conditioned by 48 hour MCF7 culture
(10.5 mL and 0.2 mL for ultracentrifugation and ExoquickTM
respectively) were determined, and are expressed here relative to
the ultracentrifugation results (n = 8; ± SEM). (B) CD63 immunoblot,
performed under non-reducing conditions, of exosomes isolated by
ultracentrifugation or ExoquickTM precipitation from 24 mL or 0.5 mL
MCF7 conditioned media respectively. Exosome pellets were
resuspended in equal volumes of PBS for both methods, and
loading was controlled by volume. *** corresponds with
P value < 0.001.
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Biosystems). Each PCR contained 1 μL reverse transcrip-
tion product and was performed in triplicate using the
Corbett Rotor-gene 2000 (Qiagen). Results for cellular
RNA reactions were normalised to small nuclear RNA
gene RNU6B, while exosomal RNA reactions were nor-
malised to cel miR-54 or miR-16. Normalisation and
relative expression analysis was performed using the Q-
Gene software [32].
Statistical analysis
Significant differences between normoxic and hypoxic
nanoparticle concentrations were determined by the Stu-
dent T test using the KaleidaGraph software (Synergy
Software), with a P value of < 0.05 considered to be sig-
nificant. Error bars represent standard error of the mean
(SEM).
Results
Exosome isolation by ultracentrifugation and ExoquickTM
precipitation
Exosomes were isolated from the conditioned media of a
breast cancer cell line (MCF7) by serial low speed centri-
fugation followed by either ultracentrifugation or pre-
cipitation with the ExoquickTM reagent. To confirm
exosomal purification, samples isolated by both methods
were examined by transmission electron microscopy and
Nanosight NTA (Figure 1). Electron microscopy revealed
the presence of vesicles within the expected size range
of exosomes (30 – 100 nm) which were positively immu-
nolabelled with CD63-specific gold particle-conjugated
antibodies (Figure 1A and 1B), confirming CD63 as an
exosomal marker in this system. Exosomes prepared by
both methods exhibited similar morphologies and sizes,
although ExoquickTM exosomes tended to form long
strings of vesicles (Figure 1B), likely as a result of the
polymer reagent. NTA of the exosome fractions using
the Nanosight microscope revealed the presence of nano-
particles with a modal size of 80 nm and 84 nm for the
ultracentrifugation and ExoquickTM samples respectively
(Figure 1C), similar to previous reports using this tech-
nology [33-36]. Immunoblotting of exosome fractions
confirmed the presence of the exosomal proteins CD63,
TSG101, flotillin-1 and cofilin (Figure 1D), as identified
in the ExoCarta database [37].
ExoquickTM is an efficient method for exosome isolation
from conditioned media
The efficiency of a novel proprietary reagent called Exo-
quickTM for exosome isolation from small volumes in
cell culture systems (< 1 mL) was compared to the trad-
itional method of ultracentrifugation. Nanosight NTA
quantitation identified that nanoparticle concentrations
were approximately 50-fold higher in exosome fractionsisolated by ExoquickTM as compared to ultracentrifu-
gation of the same conditioned media (Figure 2A;
P < 0.0001). ExoquickTM precipitation yielded a mean
concentration of 2.56 × 1011 ± 1.13 × 1010 nanoparticles
per mL of conditioned media, while ultracentrifugation
yielded only 5.27 × 109 ± 1.31 × 109 nanoparticles per mL.
Nanosight quantitation was supported by immunoblotting
for the exosome marker CD63, which demonstrated simi-
lar band intensities for ultracentrifugation- and Exo-
quickTM-derived exosome fractions generated from 24 mL
and 0.5 mL conditioned media respectively (Figure 2B).
Hypoxic exposure of breast cancer cells increases
exosome concentration in conditioned media
To examine the impact of hypoxia on exosome release,
MCF7 breast cancer cells were exposed to moderate hy-
poxia (1% O2) in a hypoxic glovebox (Coy Laboratories).
Exosomes were isolated from the conditioned media
after 48 hours and quantitated by Nanosight NTA. Exo-
some fractions harvested from hypoxic cells demonstrated
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http://www.biomedcentral.com/1471-2407/12/421significantly higher nanoparticle concentrations when
compared with exosome fractions from the normoxic
control (1.41-fold; P= 0.0011) (Figure 3A). To examine
whether this enhancement occurred in other breast can-
cer cell lines, MDA-MB 231 and SKBR3 cells were also
studied. Exosome fractions isolated from MDA-MB 231
conditioned media yielded greater nanoparticle concen-
trations after 48 hour culture at 1% O2 (1.32-fold;
P= 0.0060) (Figure 3A). SKBR3 cells also demonstrated
an increased nanoparticle concentration in hypoxic exo-
some fractions (1.24-fold) (Figure 3A), though this did0.0E+00
2.0E+05
4.0E+05
6.0E+05
Normoxia Hypoxia (1%)
CD
63
 B
an
d 
In
te
ns
ity
 
(A
U)
0
0.5
1
1.5
2
2.5
MCF7 SKBR3 MDA-MB 231
Na
n
o
pa
rti
cl
e 
Co
n
ce
n
tr
at
io
n 
re
la
tiv
e 
to
 N
o
rm
o
xi
c 
Co
n
tr
ol
Normoxia
Hypoxia (1%)
0
1
2
3
4
5
6
7
8
9
10
0 100 200 300 400 500 600 700 800 900 1000
Na
n
o
pa
rti
cl
e 
Co
n
ce
n
tr
at
io
n
 
re
la
tiv
e 
to
 
Ce
ll 
Co
u
n
t
Nanoparticle Diameter (nm)
Normoxia
Hypoxia (0.1%)
A
C
E
Normoxia Hypoxia (1% O2)
MCF7
56kDCD63
** **
Figure 3 Hypoxic enhancement of exosome release by breast cancer
for 48 hours. Exosomes were isolated from conditioned media by Exoquick
NTA and expressed relative to the normoxic control. Data for each sample
(B) MCF7, SKBR3 and MDA-MB 231 cells were cultured at 0.1% O2 for 24 ho
(C) CD63 immunoblot of MCF7 ExoquickTM precipitants from a 48 hour cul
(D) CD63 immunoblot of MDA-MB 231 ExoquickTM precipitants from a 24 h
quantitation. (E, F) Nanoparticle size distribution profiles obtained by NTA f
final cell counts for normoxia and hypoxia (E) and relative nanoparticle size
nanoparticle concentration (F). All CD63 immunoblots were performed und
*, **, and *** correspond with P values <0.05, <0.01 and <0.001 respectivelnot achieve statistical significance (P= 0.16). To deter-
mine if the observed increases in nanoparticle concen-
tration corresponded to exosome levels, ExoquickTM
precipitants were assessed for levels of the exosome
marker CD63 by immunoblotting (Figure 3C). CD63
was present in protein extracts from exosomes purified
in this way and increased CD63 levels were observed in
hypoxic exosome fractions after exposure to 1% O2 for
48 hours, as shown here for MCF7 (Figure 3C). Band in-
tensity quantitation revealed a significant increase in
CD63 band intensity for hypoxic MCF7 exosome0
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http://www.biomedcentral.com/1471-2407/12/421fractions (P= 0.0096), supporting the observations made
using the Nanosight. This increase in CD63 is likely to
represent hypoxic enhancement of exosome release as
cellular CD63 levels were not enhanced by hypoxic ex-
posure (results not shown). Similar results were ob-
served for immunoblots of SKBR3 exosome fractions for
the exosome markers CD63 and CD9, and band inten-
sity quantitation of these immunoblots demonstrated
increased CD63 and CD9 in hypoxic exosome fractions
(P= 0.062 and P= 0.017) (Additional File 3A).
To assess whether a more severe hypoxic exposure
would affect exosome release in a similar manner, cells
were cultured at 0.1% O2 for 24 hours, prior to Exo-
quickTM precipitation and NTA (Figure 3B). Due to the
severity of the hypoxic exposure, the duration of expos-
ure was decreased to 24 hours to limit the impact on cell
viability and growth (Additional File 1). Nanoparticle
concentrations were normalised to cell numbers at the
time of harvest where the severe hypoxic exposure re-
sulted in a significant reduction in cell growth, such as
for MCF7 and SKBR3 cell line experiments. Exosome
fractions isolated from hypoxic breast cancer cells con-
tained significantly higher nanoparticle concentrations
per cell count compared to the normoxic control exo-
some fractions for all three cell lines (Figure 3B). MCF7
culture-derived ExoquickTM precipitants demonstrated a
1.77-fold increase in total nanoparticle concentration
(P= 0.016) after 24 hours at 0.1% O2 (Figure 3B). SKBR3
cells experienced a 1.94-fold increase in total nanoparticle
concentration (P= 0.00019) and MDA-MB 231 cells re-
leased 2-fold more nanoparticles (P= 0.0098) (Figure 3B).
These data were supported by CD63 immunoblotting of
exosomes purified from other breast cancer cell lines
under normoxic and hypoxic conditions, MDA-MB 231
(Figure 3D) and SKBR3 (Additional File 3B) which re-
vealed increased levels of CD63 and CD9 present in the
hypoxic exosome fractions.A
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Figure 4 Exosome release is modulated by induction of hypoxia indu
1 mM DMOG for 24 hours. Exosomes were isolated and quantitated by NT
transfected with negative control (NC) siRNA or siRNA targeting HIF-1α prio
ExoquickTM and quantitated by NTA (n = 4; ± SEM). Annotations *, **, and *The increased nanoparticle concentrations for the
hypoxic exosome fractions corresponded with peaks ap-
proximately 80 to 90 nm (Figure 3E), within the expected
size range of exosomes. There were no qualitative differ-
ences identified between the hypoxic and normoxic exo-
some size distribution profiles when normalised to total
nanoparticle concentrations (for example of MCF7 exo-
somes see Figure 3F). This suggests that exposure to
hypoxia did not affect the size profile of the exosome
fractions, and establishes that the observed hypoxic in-
creases in nanoparticle concentrations represent a change
in concentration of a similar population of nanovesicles
(i.e. exosomes) to that present in the normoxic control.
To examine for a potential role of the HIF oxygen
sensing system in promoting exosome release, the in-
fluence of the HIF hydroxylase inhibitor, DMOG, a
2-oxoglutarate analogue which induces a HIF response,
was considered. Treatment of MDA MB-231 cells with
1 mM DMOG for 24 hours resulted in a modest yet sig-
nificant increase in exosome release as determined by
NTA quantitation (1.23-fold; P= 0.00095) (Figure 4A).
Furthermore, MDA-MB 231 cells transfected with a
siRNA targeting HIF-1α failed to show significant en-
hancement of exosome release after hypoxic exposure
(1.12-fold; P= 0.39) compared to cells transfected with a
negative control siRNA (1.45-fold; P= 0.027) (Figure 4B).
There was a significant difference in nanoparticle con-
centration between the HIF siRNA transfection and the
negative control siRNA under hypoxia (P= 0.031). These
data suggest a putative role for HIF signalling in the
hypoxic enhancement of exosome release.
Hypoxic regulation of exosomal miR-210
In order to study qualitative differences in exosomes
released under hypoxic conditions, several candidate
miRNAs were first considered for their suitability as ex-
tracellular control genes during hypoxia. MCF7 cellularB
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Figure 5 Cellular and exosomal microRNA expression levels in
response to hypoxia. (A) Mean normalised expression levels of
MCF7 cellular miRNAs as determined by miRNA-specific Taqman
real-time RT-PCR assays in response to 1% O2 for 48 hours and
normalised to RNU6B. Expression values are presented relative to
normoxic control. (n = 3; ± SEM). (B, C) ExoquickTM precipitants
isolated from MCF7 cell culture after 48 hours at 1% O2 were spiked
with cel miR-54 and used for RNA extractions. This exosomal RNA
was then assayed for miR-16, let7a, miR-210 and cel miR-54 by
real-time RT-PCR and normalised to exogenous cel miR-54 (B) or
endogenous miR-16 (C) (± SEM). Normoxia n= 4; Hypoxia n= 5.
** corresponds with P value < 0.01.
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assayed for the miRNAs miR-16, let7a and miR-21 using
miRNA-specific Taqman real-time RT-PCR assays
(Figure 5A). These miRNAs were chosen as potential
candidates given their previous use as extracellular con-
trol genes or reported presence in exosomes [38-41].
The hypoxically regulated miR-210 was also assayed.
Mean normalised expression levels of cellular miR-16
and let7a did not change significantly with exposure to
hypoxia (1.03-fold (P= 0.86) and 0.99-fold (P= 0.96) re-
spectively). Expression levels of cellular miR-21 were
increased after hypoxic culture (2.77-fold), however this
did not achieve statistical significance (P= 0.11). Levels
of cellular miR-210 demonstrated a significant increase
after hypoxic exposure (12.49-fold; P= 0. 0025) as previ-
ously reported [42].
To determine if miR-210 levels were also elevated in
exosomal RNA and to further investigate miR-16 and
let7a as extracellular control genes, ExoquickTM precipi-
tants from MCF7 conditioned media after 48 hours at nor-
moxia or 1% O2 were spiked with synthetic Caenorhabditis
elegans miR-54 (cel miR-54) to act as an exogenous control
[31,41]. RNA isolated from ExoquickTM precipitants were
then assayed for miR-210, miR-16, let7a and cel miR-54
(Figure 5B). Although miR-16 and miR-210 were amplified
successfully from the exosome fractions, let7A failed
to amplify, in spite of previous reports of its presence
in exosomes [43,44]. When normalised to exogenous cel
miR-54, exosomal miR-16 levels were relatively con-
sistent between normoxic and hypoxic samples (0.86-fold;
P=0.54), and miR-210 levels were significantly higher for
hypoxic exosomal RNA samples (6.44-fold; P= 0.0026).
When miR-210 was normalised to miR-16, the extent of
hypoxic induction (6.23-fold) was equally apparent, al-
though this difference was less significant (P= 0.052)
(Figure 5C).
Discussion
Hypoxia is an important feature of tumours, and is asso-
ciated with aggressive tumour phenotypes and poor pa-
tient outcomes [17]. Tumours can communicate with
surrounding tissue to promote tumour progression and
invasion through the release of exosomes [5,6,45,46]. In
this study, we investigated the impact of hypoxia, a clin-
ically important feature of tumour progression, on exo-
some release by breast cancer cells. Here we present
evidence that hypoxia enhances the release of exosomes
by three different breast cancer cell lines, and that this
process may be mediated, at least in part, by the HIF
oxygen sensing pathway.
Exosomes were isolated by both ultracentrifugation
and ExoquickTM and were identifiable by their morph-
ology and CD63 immunolabelling. These two purifica-
tion methods were found to be comparable with regardto nanovesicle size and morphology as determined by
NTA and electron microscopy. To our knowledge, this
is the first such qualitative comparison of cell culture-
derived exosomes currently available for these two
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tions have been made in a clinical setting [47]. Exo-
quickTM precipitation was found to be significantly more
efficient at isolating exosomes, as determined by direct
quantitation by Nanosight NTA, supporting previous
comparisons using protein quantitation and immuno-
blotting [28]. From our experience, the efficiency of Exo-
quickTM can allow exosome isolation and detection from
as little as 10 μL of conditioned media (data not shown).
There is an increasing body of evidence that tumour
cell-derived exosomes play important roles in angiogen-
esis [5], cancer cell invasion [45], metastasis [10] and im-
munosuppression [8,9] to promote tumour progression.
Therefore, understanding the stimuli which promote
exosome release by tumour cells is important in under-
standing tumour development. Here we present evi-
dence that hypoxia promotes the release of exosome-
sized nanoparticles. Exposure of breast cancer cells to
modest (1%) and severe (0.1%) hypoxia resulted in mean
increases of 32.3 ± 4.8% and 90.9 ± 7.1% of exosome-
sized nanoparticles harvested from the conditioned
media respectively. This is the first report to provide dir-
ect exosome quantitation after hypoxic exposure of cells.
Previous studies have noted observations of the hypoxic
enhancement of secretions of specific proteins, of puta-
tive exosomal origin [21,48,49]. Our study offers the
possible explanation that the increased concentrations of
these proteins may be due to increased release of exo-
somes under hypoxia. Recent data failed to identify a
significant difference in the concentration of exosomes
released by hypoxic endothelial cells [36]. This could be
explained by the modest hypoxic exposure (2% O2) per-
formed, which is consistent with our observation that
hypoxic enhancement of exosome release was relative to
the severity of the hypoxic treatment. Alternatively, the
substantial phenotypic differences between endothelial
cells and epithelial tumour cells could also explain a lack
of hypoxic enhancement.
HIF induction may play a role in the hypoxic enhance-
ment of exosome release, which was supported here by
manipulation of the HIF oxygen sensing pathway using
DMOG and siRNA interference. Further circumstantial
evidence for this putative role of HIF is provided by
HIF-1α dependent secretion of HSP90α by dermal fibro-
blasts [50], potentially via exosomes [51]. However, it is
important to recognise that the modest enhancement of
exosome release experienced during HIF activation
under normoxia (i.e. DMOG treatment) and incomplete
abrogation of hypoxic enhancement by HIF siRNA sug-
gests that other hypoxic responses may be involved.
Given the role for exosomes in tumour progression,
increased release of exosomes by hypoxic tumour cells
could translate to increased tumour invasion and pro-
gression during hypoxia. In addition to the effect ofincreased exosome numbers, hypoxic tumour-derived
exosomes contain various pro-angiogenic factors which
allow them to promote angiogenesis and endothelial cell
activation [20,21]. However, these studies did not iden-
tify if these proteins were an inherent component of
exosomal cargo, or were induced by hypoxic exposure.
Recent comparison of normoxic and hypoxic endothelial
cell-derived exosomes identified that both protein and
mRNA exosomal cargo are affected by hypoxia [36].
How exosomal miRNAs might mediate hypoxic signal-
ling requires further investigation. Here we have pre-
sented data which suggest that the miRNA miR-210 is
elevated in hypoxic exosomes. This could play a role in
promoting tumour progression in response to hypoxia,
as miR-210 can promote endothelial cell tubulogenesis
[52], as well as repressing DNA repair pathways [53].
One interesting possibility is that exosomal miRNAs
may promote hypoxic signalling, for example miR-424
or miR-31 activation of HIF-1α independent of hypoxia
[54,55]. Of note, miR-424 is induced by hypoxia [54],
and has been identified in tumour-derived exosomes
[38]. In vivo treatment with melanoma-derived exosomes
promotes HIF-1α mRNA expression in sentinel lymph
nodes [10], highlighting the importance of further stud-
ies into exosome-mediated hypoxic signalling.
Conclusions
Breast cancer cells release greater levels of exosomes
when exposed to hypoxia, and this has important impli-
cations for how tumour cells might signal to surround-
ing tissue in the tumour microenvironment. Hypoxic
exosomes contained higher levels of miR-210, high-
lighting the potential for qualitative differences between
normoxic and hypoxic exosomes. Given the impact of
hypoxia on invasive cellular phenotypes, it will also be
important to identify if in addition to secreting higher
levels of exosomes, hypoxia promotes tumour growth by
increasing the invasive signals from tumour-derived
exosomes.
Additional files
Additional File 1: Impact of hypoxia on cell growth and viability.
(A, B) MCF7, SKBR3 and MDA-MB 231 breast cancer cells were cultured
for 48 hours under normoxia or 1% O2. Cell counts were performed for
each well after hypoxic exposure (A) and cell viability was determined by
Trypan blue exclusion (B) (n=4; ± SEM). (C, D) MCF7, SKBR3 and MDA-MB
231 breast cancer cells were cultured for 24 hours under normoxia or
0.1% O2 and cell counts (C) and viability (D) data were obtained as
described above (n=4; ± SEM). ** corresponds with P value < 0.01.
Additional File 2: Nanosight video recording of MCF7 ExoquickTM-
isolated exosomes. Representative video of MCF7 exosomes isolated by
ExoquickTM precipitation as visualised by Nanosight LM10 microscope
using a 405 nm laser.
Additional File 3: Hypoxic enhancement of exosome release as
detected by CD63 immunoblot. (A) CD63 and CD9 immunoblot of
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http://www.biomedcentral.com/1471-2407/12/421SKBR3 ExoquickTM precipitants from a 48 hour culture under normoxia or
1% O2, including band intensity quantitation. (B) CD63 immunoblot of
SKBR3 ExoquickTM precipitants from a 24 hour culture under normoxia or
0.1% O2, including band intensity quantitation. All CD63 immunoblots
were performed under non-reducing conditions as described
previously [16].
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